Gulf Pharmaceutical Industries

1. Company Overview & Earnings Context

Julphar reported significantly stronger Q1 2026 profitability driven by gross margin expansion, EBITDA growth, lower finance costs, and operational efficiency improvements despite a slight decline in revenue. The Group operates across pharmaceutical manufacturing, medicines, healthcare products, and retail pharmacy operations across the UAE and international markets.

The company highlighted that geopolitical disruptions, supply chain challenges, and inflationary pressures impacted revenue during the quarter, while management continued focusing on market expansion, operational efficiency, and new product launches.

2. Financial Performance Snapshot

• Revenue from continuing operations: AED 273.4M

• Gross profit: AED 119.7M

• Operating profit: AED 31.7M

• EBITDA from continuing operations: AED 44.5M

• Profit before tax from continuing operations: AED 31.9M

• Net profit from continuing operations: AED 28.4M

• Total net profit: AED 35.1M

• Basic EPS: AED 3.03 fils

Compared to Q1 2025:

• Revenue declined 3.0% YoY

• Gross profit increased 10.3% YoY

• EBITDA increased 69.8% YoY

• Net profit from continuing operations increased from AED 1.5M to AED 28.4M

3. Operational Highlights & Key Metrics

• Total assets: AED 1.86B

• Total equity: AED 987.4M

• Cash & cash equivalents: AED 224.5M

• Inventories: AED 398.3M

• Trade & other receivables: AED 619.6M

• Bank borrowings: AED 263.8M

• Operating cash flow from continuing operations: AED 8.1M

Geographic revenue contribution:

• UAE: AED 156.7M

• Other GCC countries: AED 120.3M

• Other countries: AED 66.8M

Additional highlights:

• Three new products with five SKUs launched in the UAE

• Nine international product registrations completed outside the UAE

• Continued progress on the Saudi manufacturing facility project and in-house R&D activities

4. Key Performance Drivers

• Gross margin improvement supported stronger profitability and EBITDA growth

• Lower finance costs significantly improved bottom-line performance

• Operational efficiency and cost optimization initiatives supported margins

• Continued expansion across private and tender pharmaceutical markets in GCC countries

• New product launches and pipeline expansion supported long-term competitiveness

The company also highlighted:

• EBITDA from continuing operations increased from AED 26.2M to AED 44.5M

• Gross profit rose despite lower revenue contribution during the quarter

• Stronger operational efficiency initiatives improved financial performance

5. Outlook & Forward Guidance

• Continued focus on expanding market share across UAE, Saudi Arabia, Iraq, and Morocco

• Ongoing investment into in-house R&D, biotechnology, and specialty pharmaceutical products

• Expansion of the Saudi manufacturing facility remains a strategic priority

• Management continues focusing on operational efficiencies and supply chain diversification

• Julphar aims to strengthen its pharmaceutical portfolio through new product launches and strategic alliances

The company also noted expectations for continued healthcare sector growth in the UAE and Middle East supported by economic expansion and rising healthcare investments.

6. 🧾 Investor Takeaway

Julphar delivered significantly improved Q1 2026 profitability supported by stronger margins, operational efficiency, lower finance costs, and EBITDA growth, while continuing to expand its pharmaceutical product pipeline and regional market presence despite ongoing geopolitical and supply chain pressures.